Sernova Corp. is a Canada-based development-stage regenerative medicine company. The Company is focused on commercializing the Cell Pouch, a scalable, implantable, medical device for the transplantation and survival of therapeutic cells, which then release proteins and hormones for the long-term treatment of various diseases, such as diabetes, hemophilia and thyroid disease. The Company is also developing Sertolin and other local immune protection technologies to create an immune privileged environment and protect the Cell Pouch transplant. The Company's primary program is the clinical development of the Cell Pouch for treatment of patients with insulin-dependent diabetes. The Cell Pouch enables islets to be transplanted subcutaneously.